BioInvent International AB (SE:BINV)
:BINV
Top Page
BioInvent International AB
(BINV)
Select Model
Select Model
Rating:47Neutral
Price Target:
kr23.00
▼(-24.09% Downside)
Action:ReiteratedDate:03/01/26
The score is weighed down primarily by weak financial performance (large losses and ongoing cash burn) and bearish technicals (price below key moving averages with negative MACD). The main support comes from constructive earnings-call clinical momentum and partnerships with clear upcoming catalysts, partially offset by the near-term funding runway risk.
Positive Factors
Low Financial Leverage
Very low debt-to-equity provides durable financial flexibility for a development-stage biotech, reducing bankruptcy risk and enabling continued R&D spend or opportunistic partnerships without immediate refinancing pressure over the next 2-6 months.
Negative Factors
Persistent Operating Losses
Deep, persistent operating losses reflect ongoing heavy investment in clinical programs and limit internal funding ability. If losses persist, the company may need to raise capital, diluting shareholders and shifting focus from long-term value creation to financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Financial Leverage
Very low debt-to-equity provides durable financial flexibility for a development-stage biotech, reducing bankruptcy risk and enabling continued R&D spend or opportunistic partnerships without immediate refinancing pressure over the next 2-6 months.
Read all positive factors
BioInvent International AB (BINV) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr1.50B
Dividend YieldN/A
Average Volume (3M)91.72K
Price to Earnings (P/E)―
Beta (1Y)0.33
Revenue Growth533.73%
EPS Growth20.92%
CountrySE
Employees118
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.91
Shares Outstanding65,804,360
10 Day Avg. Volume84,851
30 Day Avg. Volume91,723
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)3.47
Price to Sales (P/S)8.54
P/FCF Ratio-7.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-4.7
Revenue Forecast (FY)kr230.22M
BioInvent International AB Business Overview & Revenue Model
Company Description
BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, Japan, and internationally. Its lead drug candidate is ...
How the Company Makes Money
BioInvent International AB generates revenue through a combination of product development partnerships, licensing agreements, and potential milestone payments from collaborations with larger pharmaceutical companies. The company often enters into ...
BioInvent International AB Earnings Call Summary
Earnings Call Date:Feb 26, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Apr 29, 2026
Earnings Call Sentiment Positive
The call presents multiple strong clinical data points (notably BI-1808 in ovarian cancer and CTCL, and BI-1206 in NHL) with supportive safety and clear near-term catalysts and collaborations with Merck and AstraZeneca. Financially, Q4 sales fell sharply due to lower contract production while full-year sales increased materially driven by one-time items; operating costs and losses rose and the company states it is financed for only the next 12 months, meaning further financing or partnering will be needed to sustain a larger pivotal development plan. Overall, the positive clinical momentum and strategic partnerships outweigh short-term financial and execution risks, but upcoming readouts will be critical for de-risking future funding and pivotal starts.Positive Updates
Strong BI-1808 clinical efficacy in ovarian cancer (combo with pembrolizumab)
Phase IIa combination data in recurrent ovarian cancer: 24% overall response rate (ORR) and 57% disease control rate (DCR) with 21 evaluable ovarian cancer patients; dataset maturing with additional partial response and conversion of stable disease to PR, and a favorable safety profile.
Negative Updates
Sharp Q4 2025 net sales decline
Q4 2025 net sales SEK 3.0 million vs SEK 21.4 million in Q4 2024 — a decrease of SEK 18.4 million (~-86%), primarily due to lower production revenues for antibodies for customers.
Read all updates
Q4-2025 Updates
Positive
Negative
Strong BI-1808 clinical efficacy in ovarian cancer (combo with pembrolizumab)
Phase IIa combination data in recurrent ovarian cancer: 24% overall response rate (ORR) and 57% disease control rate (DCR) with 21 evaluable ovarian cancer patients; dataset maturing with additional partial response and conversion of stable disease to PR, and a favorable safety profile.
Read all positive updates
Company Guidance
The management outlined a dense near‑term catalyst calendar and clear go/no‑go signals: clinical readouts are expected mid‑2026 (first Phase IIa BI‑1808+pembro in CTCL; additional BI‑1206 triplet NHL data) and in 2H‑2026 (further BI‑1808+pembro solid‑tumor data and first readout from BI‑1206+pembro in first‑line NSCLC and uveal melanoma), with concrete 2027 inflection points including completion of BI‑1808 monotherapy dose optimization in 1H‑2027 and potential pivotal starts (BI‑1808 pivotal in 2H‑2027; BI‑1206 NHL pivotal potentially 1H‑2027; BI‑1206 Phase IIb in NSCLC possibly 2H‑2027). Key clinical metrics already reported: BI‑1808 ovarian combo ORR 24% and disease control rate 57% (21 ovarian patients available), BI‑1808 CTCL monotherapy 46% ORR and 92% disease control in 13 evaluable CTCL patients (including a CR >1 year), BI‑1206 triplet in NHL ~80% ORR and 100% disease control (activity across follicular, marginal zone and mantle cell; current cohort ~30 patients), and a target benchmark of ~60% ORR for BI‑1206 in first‑line NSCLC to consider advancement. Financially, Q4‑2025 net sales were SEK 3m (vs SEK 21.4m a year earlier), full‑year net sales SEK 226m (vs SEK 45m), Q4 operating costs SEK 132m (Q4‑2024 SEK 147m), full‑year operating costs SEK 578m (2024 SEK 516m), Q4 result −SEK 125.8m and full‑year result −SEK 332.9m, with liquid funds/current investments of SEK 593m and the company assessed as financed for the coming 12 months.BioInvent International AB Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
66
Positive
Cash Flow
30
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 226.50M | 44.69M | 71.46M | 326.13M | 19.38M |
| Gross Profit | 226.50M | 44.69M | 71.46M | 326.13M | 19.38M |
| EBITDA | -331.52M | -409.38M | -312.71M | -27.13M | -263.32M |
| Net Income | -332.86M | -429.38M | -330.30M | -34.09M | -278.96M |
Balance Sheet | |||||
| Total Assets | 671.20M | 989.24M | 1.40B | 1.71B | 1.45B |
| Cash, Cash Equivalents and Short-Term Investments | 592.75M | 867.16M | 1.07B | 1.02B | 1.08B |
| Total Debt | 9.68M | 17.41M | 23.24M | 26.96M | 28.37M |
| Total Liabilities | 113.59M | 103.42M | 90.45M | 106.09M | 80.32M |
| Stockholders Equity | 557.62M | 885.82M | 1.31B | 1.61B | 1.37B |
Cash Flow | |||||
| Free Cash Flow | -255.01M | -390.50M | -355.00M | -53.60M | -259.10M |
| Operating Cash Flow | -247.75M | -380.47M | -341.69M | -41.23M | -245.84M |
| Investing Cash Flow | 180.13M | 564.35M | 59.68M | -628.85M | -467.54M |
| Financing Cash Flow | -8.98M | -8.46M | 23.14M | 273.49M | 894.87M |
BioInvent International AB Technical Analysis
Negative
30.30
Price Trends
24.60
Negative
27.00
Negative
30.02
Negative
Market Momentum
-0.55
Negative
44.25
Neutral
25.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:BINV, the sentiment is Negative. The current price of 30.3 is above the 20-day moving average (MA) of 22.51, above the 50-day MA of 24.60, and above the 200-day MA of 30.02, indicating a bearish trend. The MACD of -0.55 indicates Negative momentum. The RSI at 44.25 is Neutral, neither overbought nor oversold. The STOCH value of 25.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:BINV.
BioInvent International AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | kr2.10B | 9.60 | 167.77% | ― | 2687.51% | ― | |
56 Neutral | kr3.13B | -5.27 | ― | ― | -5.69% | 21.58% | |
55 Neutral | kr974.56M | 7.07 | 81.19% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | kr2.81B | -5.68 | -49.96% | ― | -91.85% | -6.65% | |
47 Neutral | kr1.50B | -5.81 | -47.20% | ― | 533.73% | 20.92% | |
45 Neutral | kr1.39B | -7.05 | -35.03% | ― | ― | 25.14% |
* Healthcare Sector Average
SE:BINV
BioInvent International AB
22.80
-4.30
-15.87%
SE:HNSA
Hansa Biopharma AB
30.72
9.22
42.88%
SE:SANION
Saniona AB
15.21
8.54
128.04%
SE:VICO
Vicore Pharma Holding AB
9.97
3.47
53.38%
SE:XSPRAY
Xspray Pharma AB
30.25
-1.18
-3.74%
SE:CANTA
Cantargia AB
3.92
2.51
178.01%
BioInvent International AB Corporate Events
BioInvent doubles down on lead cancer antibodies as 2026 data catalysts loom
Feb 26, 2026
BioInvent has sharpened its clinical focus and resource allocation in 2025 to advance its lead oncology assets BI-1808 and BI-1206, pausing earlier-stage programs to maximize the probability of success and near-term value. The company reported imp...
BioInvent to Present 2025 Year-End Results in Investor Webcast
Feb 26, 2026
BioInvent International AB is a clinical-stage biotechnology company specializing in immuno-oncology, developing novel immuno-modulatory antibody therapies for hematological cancers and solid tumors. Leveraging its proprietary F.I.R.S.T. discovery...
BioInvent Taps Industry Heavyweights for Board as Cancer Pipeline Advances
Feb 23, 2026
BioInvent has nominated global life sciences executive Kate Hermans and veteran healthcare investor Scott Zinober to join its Board of Directors, with their elections to be put to shareholders at the April 29, 2026 AGM. The move comes as the compa...
BioInvent Posts Strong Interim Data for BI‑1808 and KEYTRUDA Combo in Recurrent Ovarian Cancer
Jan 5, 2026
BioInvent International has reported encouraging interim Phase 2a data for its first‑in‑class anti‑TNFR2 antibody BI‑1808 in combination with Merck’s anti‑PD‑1 therapy KEYTRUDA (pembrolizumab) in patients ...
BioInvent Steps Up Investor Outreach with Series of 2026 Healthcare Conferences
Dec 18, 2025
BioInvent International AB will seek to deepen engagement with global investors and industry partners in January 2026 through participation in several high-profile investor and healthcare conferences in San Francisco and Stockholm. The companyR...
BioInvent Reports Promising Phase 2a Trial Results for NHL Treatment
Dec 8, 2025
BioInvent International AB announced promising early data from its Phase 2a trial of BI-1206 in combination with rituximab and Calquence for the treatment of relapsed/refractory non-Hodgkin’s lymphoma (NHL). The trial showed an 80% overall r...
BioInvent’s BI-1808 Shows Promise in Early Phase 2a CTCL Trial
Dec 7, 2025
BioInvent International AB has presented promising early Phase 2a data for its BI-1808 monotherapy in treating cutaneous T-cell lymphoma (CTCL) at the ASH 2025 meeting. The trial showed a 46% objective response rate and a 92% disease control rate ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.